NCT00667576 is a Phase 2 clinical trial of Maxacalcitol in Chronic Kidney Disease on Hemodialysis, sponsored by Abbott.

Who is sponsoring NCT00667576?

NCT00667576 is sponsored by Abbott.

What drugs are being tested in NCT00667576?

Interventions in NCT00667576: Maxacalcitol, Paricalcitol.

What condition does NCT00667576 study?

NCT00667576 studies Chronic Kidney Disease on Hemodialysis, Secondary Hyperparathyroidism.

Is NCT00667576 still recruiting?

NCT00667576 is currently completed. Last updated 18 January 2012.

Are results published for NCT00667576?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2012-01-18 · How we verify

NCT00667576

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Late Phase 2 Study of Paricalcitol Injection: Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism (Examination of Initial Dose and Incremental Dose)

Completed Phase 2 Results posted Last updated 18 January 2012

What this trial tests

Phase 2 trial testing Maxacalcitol in Chronic Kidney Disease on Hemodialysis in 153 participants. Completed in 1 March 2009.

Timeline

1 April 2008

Primary endpoint
1 March 2009

1 March 2009

Quick facts

Lead sponsor	Abbott
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	153
Start date	1 April 2008
Primary completion	1 March 2009
Estimated completion	1 March 2009
Sites	12 locations across Japan

Drugs / interventions tested

Maxacalcitol (MAXACALCITOL) — full drug profile →
Paricalcitol (PARICALCITOL) — full drug profile →

Conditions studied

Chronic Kidney Disease on Hemodialysis — all drugs for Chronic Kidney Disease on Hemodialysis →
Secondary Hyperparathyroidism — all drugs for Secondary Hyperparathyroidism →

Sponsor

Abbott — full company profile →

Who can join

20 and older, any sex, with Chronic Kidney Disease on Hemodialysis or Secondary Hyperparathyroidism. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percentage of Subjects With ≥ 50% Decrease From Baseline in Intact Parathyroid Hormone (iPTH) Serum Level
Time frame: Baseline to Week 13 (Final Visit)

Sponsor's own description

The purpose of this study was to investigate the initial dose and dose adjustment range for paricalcitol injection in patients with chronic kidney disease on hemodialysis who have secondary hyperparathyroidism.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Chronic Kidney Disease on Hemodialysis

Currently open trials in the same condition.

NCT07494695 — Experience of Young Adult Kidney Patients Requiring Haemodialysis · active not recruiting

Other Abbott trials

Trials by the same sponsor.

NCT06217393 — Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia · Phase 3 · completed
NCT05370703 — A Clinical Study to Evaluate the Effect of Mobile Applications "My A:Care" and "Smart Coach" on the Lipid-lowering Treat · completed
NCT05519514 — Bio-Equivalence Study of Budesonide Prolonged-release Tablets 9 Mg In Healthy Human Adult Subjects · Phase 1 · completed
NCT04784208 — A Study to Determine the Validity and Sensitivity of 'Questionnaire to Screen for HYpothyroidism' (Q'SHY) · unknown
NCT05175131 — Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00667576 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abbott
Last refreshed: 18 January 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00667576.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing